Vaccine Development Services

Brain tumor vaccines activate the immune system to specifically eliminate tumor cells by targeting neoantigens or shared antigens, inducing T-cell-mediated anti-tumor responses. Alfa Cytology delivers comprehensive vaccine development services spanning antigen prediction, vaccine vector design, and in vitro/in vivo immune evaluations. Our platform integrates advanced technologies with personalized neoantigen screening to accelerate therapeutic translation.

Introduction to Vaccine of Brain Tumors

Brain tumor vaccines represent an advanced immunotherapy strategy designed to activate targeted immune recognition and clearance of tumor cells. By focusing on tumor-specific biomarkers-including unique neoantigens or overexpressed shared antigens-these vaccines trigger precise T-cell-mediated anti-tumor immunity. This approach leverages adaptive immune mechanisms to enhance therapeutic efficacy, providing a tailored intervention with reduced systemic toxicity compared to conventional surgical, radiotherapeutic, or chemotherapeutic modalities.

Fig 1. Peptide and heat shock protein vaccines. (LEE J, et al., 2021)

Vaccine for Brain Tumors

Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Alfa Cytology leverages its strong R&D capabilities and mature biotechnology platform to provide comprehensive technical support for the development of brain tumor vaccines. With deep scientific expertise and extensive project experience, we offer robust assistance to advance brain tumor vaccine development.

Cell-Based Vaccines

Use autologous or allogeneic tumor cells (or their lysates) as antigen sources to induce a broad anti-tumor immune response. Suitable for brain tumor patients without clearly identified neoantigens.

Virus-Based Vaccines

Employ viral vectors (e.g., adenoviruses, oncolytic viruses) to deliver tumor antigen genes and activate T-cell responses. Often used to express specific brain tumor antigens like EGFRvIII.

Peptide-Based Vaccines

Synthesize tumor-specific peptide antigens (neoantigens or shared epitopes) combined with adjuvants to enhance immunogenicity, precisely activating antigen-specific T cells. Ideal for personalized treatments with known mutation targets.

DNA & RNA Vaccines

Encode tumor antigens via plasmid DNA or mRNA to stimulate humoral and cellular immunity. Offer rapid development advantages; lipid nanoparticle (LNP)-encapsulated mRNA vaccines can target the immune microenvironment in brain tumors.

Workflow of Vaccine Development

Antigen Discovery and Validation

Based on tumor genomic and immunogenicity databases, combined with machine learning algorithms, screen for highly specific brain tumor antigens (such as mutated proteins or neoantigens). Validate their potential to activate adaptive immunity through T-cell proliferation assays.

Vaccine Design and Construction

Customize vaccine formats according to antigen characteristics (e.g., mRNA encoding multi-antigen libraries, viral vectors delivering immunostimulatory factors). Integrate targeted delivery technologies (such as nanoparticle modifications) to overcome the limitations imposed by the blood-brain barrier.

In Vitro Functional Validation

Utilize humanized immune cell–tumor co-culture systems to assess the efficiency of vaccine-induced antigen cross-presentation and T-cell tumor-killing activity. Simultaneously verify the vaccine's ability to reverse immune suppression within the brain microenvironment.

In Vivo Efficacy Evaluation

Investigate therapeutic strategies in immune-reconstituted animal models. Quantify the vaccine's effectiveness in eliminating orthotopic brain tumors and inducing systemic immune memory formation through multimodal imaging and immunohistochemical analyses.

Leveraging an AI-driven antigen screening platform and multi-omics integration technologies, Alfa Cytology provides comprehensive, end-to-end development services for brain tumor vaccines-from neoantigen prediction and vector optimization to preclinical efficacy validation-empowering personalized immunotherapy. We invite you to contact our scientific team for customized solutions.

Reference

1. LEE J, UY B R, LIAU L M. Brain Tumor Vaccines [J]. Neurosurgery clinics of North America, 2021, 32(2): 225-34.